Compare Novo Nordisk A/S (NVO) vs Banco Santander SA (SAN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novo Nordisk A/S vs Banco Santander SA — how do they compare? Novo Nordisk A/S trades at $38.4 (market cap $165.31B), while Banco Santander SA trades at $13.49 (market cap $192.86B). The key difference: Banco Santander SA is the larger of the two by market cap, and Novo Nordisk A/S pays the higher dividend (4.71%). Which is the better fit depends on your goals — on Pluang, investors hold Novo Nordisk A/S for 116 Days and Banco Santander SA for 55 Days on average.
| NVO | SAN | |
|---|---|---|
Market Cap | $165.31B | $192.86B |
Volume | 11,432,838 | 10,644,519 |
Sector | Health | Financials |
52-Week High | $63.98 | $15.05 |
52-Week Low | $35.29 | $9.65 |
Typical Hold Time | 116 Days | 55 Days |
Enterprise Value | $179.56B | $360.86B |
Dividend Yield | 4.71% | 2.06% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novo Nordisk (NVO) trades at $38.26, up 1.95% today, with a bullish technical signal supported by oscillators like RSI at 20.06 (buy signal). The company shows strong fundamentals with a P/E of 9.66, net income margin of 35.35%, and consistent earnings beats in recent quarters. Recent news highlights pipeline developments, including a Wegovy pill study showing continued weight loss and a $4 billion licensing deal, though an FDA delay for a hemophilia drug poses a near-term headwind.
The outlook remains positive with a consensus price target of $44.67, implying 17% upside, driven by robust profitability and growth in GLP-1 therapies. Risks include competitive pressure from Eli Lilly, regulatory delays, and reliance on obesity/diabetes drugs. Analyst sentiment is bullish (59% buy ratings), but investors should monitor execution amid high expectations.
Banco Santander (SAN) trades at $13.66, down 2.5% today, with technical indicators showing bearish momentum. The company reported strong fundamentals with Q2 2026 net income of $14.10 billion and a 26.25% net margin, though cash flow trends show recent operational challenges. Recent developments include the completion of the Webster Financial acquisition, expanding Santander's U.S. presence and diversification.
Outlook remains mixed with analyst consensus at 'Moderate Buy' (64% buy ratings) but technical weakness. Key opportunities include record profitability and strategic acquisitions, while risks involve declining cash flows and high debt levels. The stock's valuation appears reasonable with P/E of 13.55 and P/B of 1.58.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →About Banco Santander SA
Santander's focus is on retail and commercial banking. Latin America is geographically the largest operation, with Brazil by far the largest. Its continental European business is still mainly Iberian. Santander's U.K. presence is the result of the acquisition of building society Abbey. In the U.S., Santander operates a vehicle finance business and a regional bank focused on the Northeastern states.
Read more on SAN →
